SMS Pharmaceuticals Ltd.

399.15+1.2 (+0.30%)

8 Sep, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

SMS Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	214.10	245.19	518.04	579.29	603.19	438.12	462.68	464.91	411.95	563.18	519.87	522.05	709.26	782.75	886.87	897.79
Cost of Operating Revenue	150.59	240.04	408.58	435.37	446.49	338.50	337.31	339.97	294.09	392.34	348.14	411.91	512.22	538.58	606.05	625.54
Gross Profit	63.51	5.15	109.46	143.92	156.70	99.62	125.37	124.94	117.85	170.84	171.73	110.14	197.04	244.17	280.82	272.25
Gross Margin	29.7	2.1	21.1	24.8	26.0	22.7	27.1	26.9	28.6	30.3	33.0	21.1	27.8	31.2	31.7	30.3
Total Operating Expenses	189.12	294.11	473.24	510.17	533.38	382.50	389.20	394.09	354.04	464.34	437.69	499.60	624.15	678.08	755.24	765.09
Operating Profit	24.98	-48.92	44.80	69.12	69.81	55.62	73.47	70.83	57.90	98.84	82.18	22.45	85.11	104.67	131.63	132.70
Operating Margin	11.7	-20.0	8.6	11.9	11.6	12.7	15.9	15.2	14.1	17.5	15.8	4.3	12.0	13.4	14.8	14.8
Financing Income/(Expense) - Net	-23.60	-24.17	-12.29	-1.61	-14.48	-14.75	-14.38	-10.55	-10.06	-10.28	-15.74	-17.26	-19.80	-12.78	-17.13	-22.73
Profit before Taxes	1.42	29.66	32.02	67.48	56.27	41.58	60.35	62.35	50.76	91.12	68.50	5.35	66.11	92.34	116.64	119.47
Income Taxes	0.28	4.34	11.63	32.24	14.63	5.97	19.89	20.90	18.07	30.16	0.62	1.47	16.91	24.94	28.64	29.99
Profit after Tax	1.14	25.32	20.38	35.24	40.89	28.49	31.75	40.05	31.57	62.53	62.22	-7.06	49.83	69.14	101.99	102.41
PAT Margin	0.5	10.3	3.9	6.1	6.8	6.5	6.9	8.6	7.7	11.1	12.0	-1.4	7.0	8.8	11.5	11.4
EPS - Basic - ex Extraordinary Items	0.11	2.53	2.41	4.16	0.48	3.37	3.75	4.73	3.73	7.39	7.35	-0.83	5.89	8.16	11.15	11.15
EPS - Diluted - ex Extraordinary Items	0.11	2.53	2.41	4.16	0.48	3.37	3.75	4.73	3.73	7.39	7.35	-0.83	5.89	8.16	11.15	11.15
EBIT	24.98	-48.92	44.80	69.12	69.81	55.62	73.47	70.83	57.90	98.84	82.18	22.45	85.11	104.67	131.63	132.70
EBITDA	37.62	-35.20	57.66	86.28	89.25	74.80	93.37	90.10	79.97	121.12	114.33	54.58	116.63	139.00	171.55	172.86
EBITDA Margin	17.6	-14.4	11.1	14.9	14.8	17.1	20.2	19.4	19.4	21.5	22.0	10.5	16.4	17.8	19.3	19.3

Balance Sheet

Abridged

Understanding Balance Sheet

SMS Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

We don't have enough data to show Annual Consolidated Balance Sheet data for SMS Pharmaceuticals Ltd.

Cash Flow

Abridged

Understanding Cash Flow Statement

SMS Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

We don't have enough data to show Annual Consolidated Cash Flow data for SMS Pharmaceuticals Ltd.

Business Segment Analysis

FY End:

Mar 26

SMS Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 130.56 Cr

Revenue / Sales

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 886.87 Cr

Assets

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 1,362.44 Cr

Operating Income

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 131.63 Cr

Regional Segment Analysis

FY End:

Mar 26

SMS Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Exports. (67.2%)₹ 595.99 CrDomestic (32.8%)₹ 290.88 Cr

Historical Segment Analysis

Track how SMS Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Manufacturing of Active Pharmaceuticals and their intermediates	43	152	27	30	52	123	131

Frequently Asked Questions

What is the revenue of SMS Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of SMS Pharmaceuticals Ltd. is ₹ 897.79 Cr, reflecting a 1-year growth of 10.25% and a 3-year CAGR of 14.83%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of SMS Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of SMS Pharmaceuticals Ltd. is ₹ 101.99 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of SMS Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of SMS Pharmaceuticals Ltd. is approximately ₹ 132.98 Cr (based on an operating margin of 14.81%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of SMS Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of SMS Pharmaceuticals Ltd. is 11.15. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of SMS Pharmaceuticals Ltd.?

The debt-to-equity ratio of SMS Pharmaceuticals Ltd. stands at 0.46. The interest coverage ratio is 5.69x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of SMS Pharmaceuticals Ltd.?

The estimated book value per share of SMS Pharmaceuticals Ltd. is 83.91 (derived from a P/B ratio of 4.76 and market price of ₹ 399.15), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of SMS Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of SMS Pharmaceuticals Ltd. is ₹ 37.91 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does SMS Pharmaceuticals Ltd. report consolidated or standalone financials?

SMS Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.